Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial.
Cannabidiol
Osteoarthritis of the knee
Pain
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
12
08
2023
revised:
23
10
2023
accepted:
24
10
2023
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
Painful knee osteoarthritis (KOA) is common, pharmacological treatment, however, is often hampered by limited tolerability. Cannabidiol, which preclinically showed anti-inflammatory, analgesic activity, could supplement established analgesics, but robust clinical trials are lacking. The aim of our study was to investigate the effects of oral high-dose CBD administered over 8 weeks on pain, function and patient global assessment as an add-on to continued paracetamol in chronic symptomatic KOA. Prospective, randomized, placebo-controlled, double-blind, parallel-group study. Single center, Outpatient Clinic, Department of Special Anaesthesia and Pain Therapy at Medical University of Vienna, Austria. Eligibility criteria included: age: 18-98 years; painful KOA; score ≥5 on the pain subscale of the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Index; KOA confirmed by imaging. Participants were on continued dosage of paracetamol 3 g/d and randomly assigned by web-based software 1:1 to oral cannabidiol 600 mg/d (n = 43) or placebo (n = 43). Study period: 8 weeks. Primary outcome: Change in WOMAC pain subscale scores (0 = no pain, 10 = worst possible pain) from baseline to week 8 of treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT04607603. Trial is completed. The trial was conducted from October 1, 2020 to March 29, 2022. 159 patients screened, 86 randomized. Among 86 participants (mean age, 62.8 [SD 20.3] years; 60 females [69.8%]), 58 (67.4%) completed the trial. Mean baseline WOMAC pain subscale was 6.0 ± 1.1. Analysis: Intention-to-treat principal. Mean reduction in WOMAC pain subscale was 2.5 (95% CI: 1.8-3.3) in the cannabidiol group and 2.4 (95% CI: 1.7-3.2) in the placebo group with no significant group difference (p = 0.80). Adverse events were significantly more frequent with cannabidiol (cannabidiol: 135 [56%]; placebo: 105 [44%]) (p = 0.008). Rise above baseline of liver aminotransferases and gamma-glutamyltransferase was significantly more common in the cannabidiol (n = 15) than the placebo group (n = 5) (p = 0.02). In KOA patients, oral high-dose add-on cannabidiol had no additional analgesic effect compared to adding placebo to continued paracetamol. Our results do not support the use of cannabidiol as an analgesic supplement in KOA. Trigal Pharma GmbH.
Sections du résumé
Background
UNASSIGNED
Painful knee osteoarthritis (KOA) is common, pharmacological treatment, however, is often hampered by limited tolerability. Cannabidiol, which preclinically showed anti-inflammatory, analgesic activity, could supplement established analgesics, but robust clinical trials are lacking. The aim of our study was to investigate the effects of oral high-dose CBD administered over 8 weeks on pain, function and patient global assessment as an add-on to continued paracetamol in chronic symptomatic KOA.
Methods
UNASSIGNED
Prospective, randomized, placebo-controlled, double-blind, parallel-group study. Single center, Outpatient Clinic, Department of Special Anaesthesia and Pain Therapy at Medical University of Vienna, Austria. Eligibility criteria included: age: 18-98 years; painful KOA; score ≥5 on the pain subscale of the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Index; KOA confirmed by imaging. Participants were on continued dosage of paracetamol 3 g/d and randomly assigned by web-based software 1:1 to oral cannabidiol 600 mg/d (n = 43) or placebo (n = 43). Study period: 8 weeks. Primary outcome: Change in WOMAC pain subscale scores (0 = no pain, 10 = worst possible pain) from baseline to week 8 of treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT04607603. Trial is completed.
Findings
UNASSIGNED
The trial was conducted from October 1, 2020 to March 29, 2022. 159 patients screened, 86 randomized. Among 86 participants (mean age, 62.8 [SD 20.3] years; 60 females [69.8%]), 58 (67.4%) completed the trial. Mean baseline WOMAC pain subscale was 6.0 ± 1.1. Analysis: Intention-to-treat principal. Mean reduction in WOMAC pain subscale was 2.5 (95% CI: 1.8-3.3) in the cannabidiol group and 2.4 (95% CI: 1.7-3.2) in the placebo group with no significant group difference (p = 0.80). Adverse events were significantly more frequent with cannabidiol (cannabidiol: 135 [56%]; placebo: 105 [44%]) (p = 0.008). Rise above baseline of liver aminotransferases and gamma-glutamyltransferase was significantly more common in the cannabidiol (n = 15) than the placebo group (n = 5) (p = 0.02).
Interpretation
UNASSIGNED
In KOA patients, oral high-dose add-on cannabidiol had no additional analgesic effect compared to adding placebo to continued paracetamol. Our results do not support the use of cannabidiol as an analgesic supplement in KOA.
Funding
UNASSIGNED
Trigal Pharma GmbH.
Identifiants
pubmed: 38033459
doi: 10.1016/j.lanepe.2023.100777
pii: S2666-7762(23)00196-5
pmc: PMC10682664
doi:
Banques de données
ClinicalTrials.gov
['NCT04607603']
Types de publication
Journal Article
Langues
eng
Pagination
100777Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Pain. 2020 Sep 1;161(9):2191-2202
pubmed: 32345916
Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589
pubmed: 31278997
J Rheumatol. 1997 Apr;24(4):799-802
pubmed: 9101522
Pain. 2022 Jan 1;163(1):e62-e71
pubmed: 34086631
Neurology. 2018 Apr 3;90(14):e1204-e1211
pubmed: 29540584
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365
Arthritis Rheum. 1986 Aug;29(8):1039-49
pubmed: 3741515
Pain. 2021 Jul 1;162(Suppl 1):S26-S44
pubmed: 33729209
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
Rheumatology (Oxford). 2013 Jul;52(7):1303-12
pubmed: 23542612
Cannabis Cannabinoid Res. 2023 Mar 27;:
pubmed: 36971587
JAMA Neurol. 2020 May 1;77(5):613-621
pubmed: 32119035
Pain. 2022 Oct 1;163(10):1919-1928
pubmed: 35239547
Pain. 2021 Jul 1;162(Suppl 1):S67-S79
pubmed: 32804833
JAMA. 2019 Dec 10;322(22):2156-2158
pubmed: 31746958
Cannabis Cannabinoid Res. 2018 Mar 01;3(1):21-34
pubmed: 29607408
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
Ann Rheum Dis. 2020 Jun;79(6):819-828
pubmed: 32398285
Front Vet Sci. 2018 Jul 23;5:165
pubmed: 30083539
Am J Sports Med. 2022 Sep;50(11):3056-3063
pubmed: 35905305
Lancet. 2018 Mar 17;391(10125):1085-1096
pubmed: 29395273
Cochrane Database Syst Rev. 2016 Jun 07;(6):CD012230
pubmed: 27271789
Epilepsia. 2019 Feb;60(2):294-302
pubmed: 30582156
Pain. 2022 Jun 1;163(6):1206-1214
pubmed: 34510141
Curr Med Res Opin. 2006 Oct;22(10):1911-20
pubmed: 17022849
Cannabis Cannabinoid Res. 2023 Apr;8(2):348-359
pubmed: 36040362
Med J Aust. 2021 May;214(8):370-375
pubmed: 33846971
Qual Life Res. 2019 Feb;28(2):335-343
pubmed: 30229533
Semin Arthritis Rheum. 2019 Dec;49(3):337-350
pubmed: 31126594
Cochrane Database Syst Rev. 2019 Feb 25;2:CD013273
pubmed: 30801133
Eur J Pain. 2023 Apr;27(4):492-506
pubmed: 36571471
Chest. 2020 Mar;157(3):603-611
pubmed: 31689414